AMBER GOLD: Open Payments
NPI 1083205561 · HIGH POINT, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,357 in 75 payments from 15 companies in 2025. Trend: 2023 $2,144 · 2024 $567 · 2025 $1,357
Food & beverage: $1,357
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $281 |
| ABBVIE INC. | 16 | $203 |
| Almatica Pharma LLC | 8 | $144 |
| Supernus Pharmaceuticals, Inc. | 8 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| E.R. Squibb & Sons, L.L.C. | 3 | $71 |
| Neurocrine BioSciences, Inc. | 2 | $36 |
Products named: ARISTADA, VRAYLAR, LOREEV XR, Qelbree, REXULTI, TRINTELLIX, UZEDY, Auvelity.
Industry payments across NC — which companies pay providers there.
